IndraLab
Statements
reach
"Tumor necrosis factor-alpha (TNF-alpha) was found to induce type-1 plasminogen activator inhibitor (PAI-1) antigen in the human fibrosarcoma cell line HT-1080, and PAI-1 and urokinase-type plasminogen activator (u-PA) antigens in the human carcinoma cell line T-CAR1; tissue-type plasminogen activator (t-PA) antigen was not affected or slightly decreased."
reach
"The substances secreted by these cells, known as adipocytokines, include leptin, adiponectin, angiotensinogen, resistin, tumor necrosis factor alpha (TNF-alpha) receptor activating peroxisome proliferation gamma (PPAR-gamma), interleukin-6 (IL-6), insulin like growth factor-1 (IGF-1), lipoprotein lipase (LPL), and adipsin (plasminogen activator inhibitor 1 - PAI-1) [XREF_BIBR, XREF_BIBR]."
reach
"Tumour necrosis factor alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta) increased in several, but not all, cell lines the production of urokinase-type plasminogen activator (uPA), tissue-type PA (tPA) and plasminogen activator inhibitor type 1 (PAI-1) as analysed by zymography, enzyme immunoassays and Northern analysis."
reach
"Activated macrophages secreted detectable levels of TNF, and administration of exogenous TNF significantly decreased trophoblast invasiveness (P < 0.05), increased the secretion of PAI1 (P < 0.01), and completely inhibited the pro-uPA-associated caseinolytic activity by binding to the TNF receptor 1."
reach
"In this report, we demonstrate for the first time that the treatment with liraglutide, a long acting GLP-1 analogue, inhibited TNF or hyperglycaemia mediated induction of PAI-1, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 mRNA and protein expression in a human vascular endothelial cell line."
reach
"Ohkura et al. reported that xanthoangelol (1), xanthoangelol B (5), and xanthoangelol D (9) isolated from the exudates of A. keiskei suppressed production of TNFa-induced PAI-1, an inhibitor of fibrinolysis, in human umbilical vein endothelial cells (HUVECs) (Ohkura et al. 2011 )."
reach
"It has been shown that the relationship between diabetes and visceral fat is attenuated by levels of adiponectin, IL-6, TNF-alpha, and plasminogen activator inhibitor 1, indicating the possibility that adipocytokines are key in the link between visceral fat and an unfavorable metabolic profile."
reach
"In most early infected patients the level is mainly suppressed by increasing production and release of PAI-1 in response to : cytokine TNF-alpha (tissue necrosis factor- alpha) that stimulates PAI-1 release from ECs, and the adipocytes in obese subjects, interference of the renin-angiotensin system (RAAS) with loss of effective ACE2 receptors inflammatory responses that induce platelets and macrophages to release PAI-1 hypoxia that induces monocytes to release PAI-1, reduced levels of APC."
reach
", NK-T cells Kimura et al. (2004) RT Anti-tumor activity: apoptosis (DNA topoisomerase, procasparases-3, -8, -9 in human leukemia (HL60) cells Cytotoxicities: human leukemia (HL60), melanoma (CRL1579), lung cancer (A549), stomach cancer (AZ521) cells Akihisa et al. (2011) ST Cytotoxicities: human neuroblastoma cells (IMR-32, NB-39) Nishimura et al. (2007) RT Anti-hypertensive activity: vasoconstriction in rat aortic rings Matsuura et al. (2001) ST Anti-hypertensive activity: systolic blood pressure in SHRSP Anti-hyperlipidemic activity: serum VLDL (microsomal TG transfer-protein), hepatic TG (differentiation factor 1, fatty acid synthase) levels in SHRSP Ogawa et al. (2005b) AP Anti-diabetic activity: insulin-like activity Enoki et al. (2007) RT Anti-diabetic activity: chronic ingestion on borderline mild hyperglycemia (adiponectin) Ohnogi et al. (2007) RT Anti-diabetic activity: GLUT4 translocation Kawabata et al. (2011) AP Anti-diabetic activity: a-glucosidase Luo et al. (2012) ST Anti-diabetic activity: PTP1B Li et al. (2015) EXD Anti-inflammatory activity (details in the patent) Akihisa et al. (2007) LF Anti-inflammatory activity: IL-6 in TNF-a-stimulated osteosarcoma cells Shin et al. (2011) RT, AP Anti-inflammatory activity: NO, TNF-a, iNOS, COX-2, AP-1 Yasuda et al. (2014), Chang et al. (2014) AP Anti-inflammatory activity: I-jB degradation, NF-jB nuclear translocation Chang et al. (2014) RT Anti-thrombotic activity: platelet aggregation (induced by collagen, platelet-activating factor, phorbol 12-myristate 13-acetate, not thrombin) Son et al. (2014) LF Anti-viral activity: influenza virus neuraminidase Park et al. (2011) WP Anti-viral activity: SARS-CoV (viral proteases: 3CL pro , PL pro ) Park et al. (2015) RT Preventive effect against metabolic syndrome: adiponectin production Ohnogi et al. (2012b) RT Preventive effect against metabolic syndrome: adipocytes differentiation (AMPK, MAPK pathways; C/EBPs, PPARc) Zhang et al. (2013) AP Anti-oxidative activity: NQO1 induction Luo et al. (2012) WP Anti-oxidative activity: XO Kim et al. (2014) ST Whitening activity: melanin formation in B16 melanoma cells Arung et al. (2012) AP Anti-depressant activity: inhibition of MAO-B (selective), DBH Kim et al. (2013) a Plant part code: WP whole plant, RT root, AP aerial part (including stem and leaf), ST stem, LF leaf, EXD exudate; other source code: Syn syntheticAnti-tumor-promoter activity: EBV-EA by TPA Anti-tumor-initiator activity: NOR 1 Akihisa et al. (2003) EXD Anti-inflammatory activity (details in the patent) Akihisa et al. (2007) ST Cytotoxicities: human neuroblastoma (IMR-32, NBisolation from the part Nakata et al. (1999) EXD Anti-tumor-promoter activity: EBV-EA by TPA, in vivo Akihisa et al. (2003) Two-stage mouse skin carcinogenesis test Anti-tumor-initiator activity: NOR 1 Akihisa et al. (2006) ST Anti-tumor activity: apoptosis (procaspase-3, -9, Bax) in human neuroblastoma cells (IMR-32, NB-39) Nishimura et al. (2007) EXD Anti-inflammatory activity (details in the patent) Akihisa et al. (2007) Com Anti-inflammatory activity: iNOS Shin et al. (2013) Syn Anti-bacterial activity: Gram-positive bacteria Sugamoto et al. (2011) AP Anti-oxidative activity: NQO1 induction, DPPH radical scavenging Luo et al. (2012) WP Anti-oxidative activity: XO Kim et al. (2014) AP Anti-diabetic activity: a-glucosidase Luo et al. (2012) WP Anti-viral activity: SARS-CoV (3CL pro , PL pro ) Park et al. -viral activity: influenza virus neuraminidase Park et al. (2011) WP Anti-viral activity: SARS-CoV (3CL pro , PL pro ) Park et al. (2015)4,2 0 -Dihydroxy-3 0 -[(2E)-6-hydroperoxy-3methyl-7-methylene-2-octenyl]-4 0 -methoxy chalcone(7)RT Preventive effect against metabolic syndrome: adiponectin productionOhnogi et al. (2012b)Anti-inflammatory activity: TNF-a induced ET-1 (NF-jB) Sugii et al. (2005) AP Anti-viral activity: influenza virus neuraminidase Park et al. (2011) ST Anti-thrombotic activity: TNFa-induced PAI-1 Ohkura et al. (2011) WP Anti-viral activity: SARS-CoV (3CL pro , PL pro ) Park et al. -inflammatory activity: NO, iNOS, COX-2 (IjB degradation, NF-jB nuclear translocation) Chang et al. (2014) WP Anti-viral activity: SARS-CoV (3CL pro , PL pro ) Park et al. isolation from the part Nakata et al. (1999) EXD Anti-tumor-promoter activity: EBV-EA by TPA Akihisa et al. (2003) ST Cytotoxicities: human neuroblastoma (IMR-32, NB-39) Nishimura et al. (2007) ST Whitening activity: melanin formation in melanoma cells Arung et al. (2012) Deoxyxanthoangelol H (13) EXD First isolation from the part Akihisa et al. (2006) EXD Anti-inflammatory activity (details in the patent) Akihisa et al. (2007) ST Whitening activity: melanin formation in melanoma cells Arung et al. (2012) Xanthoangelol I (14) EXD Anti-tumor-promoter activity: EBV-EA by TPA Anti-tumor-initiator activity: NOR 1 Akihisa et al. (2006) ST Cytotoxicities: human neuroblastoma (IMR-32, NB-39) Nishimura et al. (2007) 2 00 -Hydroxy-xanthoangelol I (15) RT Protective effect on nerve cells (details in the patent) Onogi et al. (2004) RT Preventive effect against metabolic syndrome: adiponectin Ohnogi et al. (2012b) Xanthoangelol J (16) EXD Anti-tumor-promoter activity: EBV-EA by TPA Akihisa et al. isolation from the part Li et al. (2015)Dorsmannin A (23) EXD First isolation from the partAkihisa et al. (2006)-diabetic activity: PTP1B Li et al. (2015) Luteolin-7-O-b-D-rutinoside (44) AP First isolation from the part Park et al. (1995) AP Anti-mutagenic activity (AFB1) Park et al. (1997a)AP Anti-oxidative activity: DPPH radical scavengingKim et al. (2005)-tumor-promoter activity: EBV-EA by TPAAkihisa et al. (2003) AP Anti-diabetic activity: a-glucosidaseLuo et al. (2012) Munduleaflavanone B (52) EXD Anti-tumor-promoter activity: EBV-EA by TPAAkihisa et al. (2006) Anti-tumor-initiator activity: NOR 1 EXD anti-inflammatory activity: TPA-induced mouse ear edemaAkihisa et al. (2007) Isobavachin(53) EXD Anti-tumor-promoter activity: EBV-EA by TPA Akihisa et al. (2006) Prostratol F (54) EXD Anti-tumor-promoter activity: EBV-EA by TPA Akihisa et al. (2003) Sophoraflavanone A (55) (=8geranylnaringenin) EXD Anti-tumor-promoter activity: EBV-EA by TPA Akihisa et al. (2006) Anti-tumor-initiator activity: NOR 1 EXD Anti-inflammatory activity: TPA-induced mouse ear edema Akihisa et al. (2007) 4 0 -O-Geranylnaringenin (56) EXD Anti-tumor-promoter activity: EBV-EA by TPA Akihisa et al. (2003) Coumarins Umbelliferone (57) RT First isolation from the part Baba et al. (1990b) Scopoletin (58) RT First isolation from the part Baba et al. (1990b) Demethylsuberosin (59) AP Anti-diabetic activity: a-glucosidase Luo et al. (2012) Osthenol (60) EXD Anti-tumor-promoter activity: EBV-EA by TPA Akihisa et al. (2006) Anti-tumor-initiator activity: NOR 1 EXD Anti-inflammatory activity (details in the patent) Akihisa et al. (2007) 7-O-b-D-Glucopyranosyloxy-8-prenyl coumarinRT First isolation from the partKozawa et al. (1978) FR First isolation from the partBaba et al. 1990a) (3 0 R)-Hydroxy columbianadin(79)(=(8S,9R)-8-angeloyl oxy-8,9-dihydrooroselol) EXD Anti-tumor-promoter activity: EBV-EA by TPA Akihisa et al. isolation from the part Baba et al. (1990b) FR First isolation from the part Baba et al. (1990a) EXD Anti-tumor-initiator activity: NOR 1 Akihisa et al. (2003) EXD Anti-allergic activity: lgE-mediated mast cell activation (bhexosaninidase, LTC4, TNF-a, FceRI b-chain PLCc1, p38 MAPK, IjB-a) Kishiro et al. (2008) AP First isolation from the part Luo et al. (2012) ST Anti-diabetic activity: PTP1B Li et al. (2015)Selidinin(84)EXD Anti-inflammatory activity (details in the patent)Akihisa et al. (2007) Senecioyl khellactone (87) EXD Anti-tumor-promoter activity: EBV-EA by TPAAkihisa et al. (2003) Anti-tumor-initiator activity: NOR 1 AP Anti-diabetic activity: a-glucosidaseLuo et al. (2012)TriterpenesPregnenolone(107)AP Anti-oxidative activity: DPPH radical scavengingLuo et al. (2012)Fig. 1 continued, cynaroside (43, luteolin-7-O-b-D-glucopyranoside), luteolin-7-O-b-D-rutinoside (44), kaempferol-3-O-a-D-arabinopyranoside (46), isoquercitrin (47, quercetin-3-O-b-Dglucopyranoside), hyperoside (48, quercetin-3-O-b-Dgalactopyranoside), quercetin-3-O-a-D-arabinopyranoside (50), pregnenoloneThe reported biological activities of xanthoangelol (1) WP whole plant, RT root, AP aerial part (including stem and leaf), ST stem, LF leaf, EXD exudate; other source code: Syn syntheticConstituents from A. keiskei and their reported biological activitiesWP whole plant, RT root, AP aerial part (including stem and leaf), ST stem, LF leaf, EXD exudate, FR fruit, SD seed; other source code: Syn synthetic, Com commercialFig."
reach
"Here, we report that the p75 neurotrophin receptor (p75 NTR), a TNF receptor superfamily member up-regulated after tissue injury, blocks fibrinolysis by down-regulating the serine protease, tissue plasminogen activator (tPA), and up-regulating plasminogen activator inhibitor-1 (PAI-1)."
reach
"Although a recent study insists that inhibition of tumor necrosis factor alpha (TNF alpha) does not reduce the induction of PAI-1 by endotoxin in rats, we imagine that TNF alpha is involved in the induction of PAI-1 by endotoxin, because endotoxin treatment induces TNF alpha and administration of TNF alpha induces PAI-1 both in vitro and in vivo."
reach
"Simvastatin also attenuated the increase in expression and secretion of PAI-1 induced by TNF-alpha (16898.6 +/- 1663.3 vs 12922.1 +/- 843.9 and 5.19 +/- 3.12 vs 0.59 +/- 0.16, respectively p < 0.05), but under baseline conditions had no effect on the expression or secretion of PAI-1."
reach
"Not only hypercoagulability but also anticoagulant protein reduction contributes to thrombosis in this setting : protein C is decreased for consumption; TF pathway inhibitor (TFPI) production is impaired and is also rapidly consumed, while fibrinolysis is compromised because of endothelial PAI-1 hyperproduction stimulated by IL-1 and TNF-alpha [XREF_BIBR, XREF_BIBR, XREF_BIBR]; Vrij et coll."
reach
"Anthropometrics were evaluated and metabolic measures such as fasting serum glucose, lipid profiles, insulin, leptin, adiponectin, resistin, tumor necrosis factor alpha (TNFalpha), activated plasminogen activator inhibitor 1 (aPAI1), high sensitivity C-reactive protein (hsCRP) and angiotensin II were also assessed."